NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator

MT Newswires Live

2025/10/07

NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.

Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573392439"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573392439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573392439?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 12:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573392439","market":"nz","top_or_hot":-1,"title":"NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator","media":"MT Newswires Live","content":"<html><body><p> NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.</p><p>Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-07 12:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.</p><p>Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"標普/澳交所 200指數","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2573392439","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573392439","pubTimestamp":1759812275,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NeuroScientific Biopharmaceuticals  said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell  technology, according to a Tuesday Australian bourse filing.Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","BK4150":"赌场与赌博","MSC":"新濠影汇","NSB.AU":"NEUROSCIENTIFIC BIOPHARMACEU","XKO.AU":"标普/澳交所 300指数","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","BK4575":"芯片概念"},"translate_title":"NeuroScientific表示，用于克罗恩病患者造瘘的StemSmart疗法已获得澳大利亚监管机构批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":1.5,"XAO.AU":1.5,"XJO.AU":1.5,"MSC":1,"NSB.AU":1},"content_text":"NeuroScientific Biopharmaceuticals (ASX:NSB) said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell (MSC) technology, according to a Tuesday Australian bourse filing.Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}